DDInter1627 DDInter817
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.
Rufinamide {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Phenytoin
Phenytoin {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Rufinamide {u} (Compound) binds {v} (Gene) SCN7A
SCN7A {u} (Gene) is bound by {v} (Compound) Procainamide
Procainamide {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Rufinamide {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Oxcarbazepine
Oxcarbazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Rufinamide {u} (Compound) binds {v} (Gene) SCN2A
SCN2A {u} (Gene) is bound by {v} (Compound) Propofol
Propofol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Rufinamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gilteritinib
Rufinamide {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Cabazitaxel
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Rufinamide {u} (Compound) binds {v} (Gene) CES1
CES1 {u} (Gene) is upregulated by {v} (Compound) Chloramphenicol
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Rufinamide {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gilteritinib
Rufinamide {u} (Compound) causes {v} (Side Effect) Urinary incontinence
Urinary incontinence {u} (Side Effect) is caused by {v} (Compound) Bexarotene
Bexarotene {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Rufinamide (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Phenytoin (Compound) and Phenytoin may lead to a major life threatening interaction when taken with Gilteritinib
Rufinamide (Compound) binds SCN7A (Gene) and SCN7A (Gene) is bound by Procainamide (Compound) and Procainamide may lead to a major life threatening interaction when taken with Gilteritinib
Rufinamide (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Rufinamide (Compound) binds SCN2A (Gene) and SCN2A (Gene) is bound by Propofol (Compound) and Propofol may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Rufinamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Rufinamide (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Cabazitaxel (Compound) and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Rufinamide (Compound) binds CES1 (Gene) and CES1 (Gene) is upregulated by Chloramphenicol (Compound) and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Rufinamide (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Rufinamide (Compound) causes Urinary incontinence (Side Effect) and Urinary incontinence (Side Effect) is caused by Bexarotene (Compound) and Bexarotene may lead to a major life threatening interaction when taken with Gilteritinib